Compass Pathways (MEX:CMPSN) Research & Development: MXN2,088.23 Mil (TTM As of Mar. 2026)


MEX:CMPSN Compass Pathways PLC MEX:CMPSN
14 GF Score
Price MXN242.00
! 2 Warning Signs
View Full Analysis

What is Compass Pathways Research & Development?

Compass Pathways MEX:CMPSN 14 Research & Development is MXN2,088.23 Mil as of Mar. 2026. GuruFocus rates MEX:CMPSN with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Compass Pathways's Research & Development for the three months ended in Mar. 2026 was MXN477.51 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN2,088.23 Mil.

Compass Pathways  (MEX:CMPSN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Compass Pathways Research & Development Related Terms

Compass Pathways Research & Development Historical Data

* Premium members only.

The historical data trend for Compass Pathways's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Pathways Research & Development Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 903.17 1,268.27 1,485.55 2,482.64 2,132.52

Compass Pathways Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 631.75 571.00 501.26 538.48 477.51
MEX:CMPSN
14GF Score
Compass Pathways PLC MEX:CMPSN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,088.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN2,088.23 Mil mean?
Compass Pathways (MEX:CMPSN) has a Research & Development of MXN2,088.23 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Compass Pathways and its competitors.
Is Compass Pathways' Research & Development too high?
Compass Pathways' current Research & Development is MXN2,088.23 Mil. Overall, Compass Pathways has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Research & Development compare to MD and SGRY?
Compass Pathways' Research & Development of MXN2,088.23 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Compass Pathways and its competitors. Compass Pathways's current Research & Development is MXN2,088.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (MEX:CMPSN) has a current Research & Development of MXN2,088.23 Mil. The current Research & Development is MXN2,088.23 Mil. Compass Pathways' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Compass Pathways (MEX:CMPSN), the current Research & Development is MXN2,088.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Pathways Business Description

Other Exchanges CMPS:USA5Y6:Germany
Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
14GF Score

Get the complete analysis for MEX:CMPSN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN242.00
Price